<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824094</url>
  </required_header>
  <id_info>
    <org_study_id>A8081064</org_study_id>
    <nct_id>NCT02824094</nct_id>
  </id_info>
  <brief_title>Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC</brief_title>
  <official_title>Crizotinib (Xalkori (Registered)) Expanded Access Protocol For The Treatment Of Japanese Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Ros1 Oncogene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      Primary objective of this study is to allow access and evaluate the safety of crizotinib for&#xD;
      patients in Japan with advanced NSCLC harboring a translocation or inversion involving the&#xD;
      ROS1 oncogene.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or&#xD;
             metastatic.&#xD;
&#xD;
          -  Positive for translocation or inversion events involving the ROS1 gene as determined&#xD;
             by protocol defined test.&#xD;
&#xD;
          -  ECOG performance status 0 to 2.&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Patients with brain metastases are eligible if neurologically stable for at least 2&#xD;
             weeks and have no ongoing requirement for corticosteroids.&#xD;
&#xD;
          -  Male patients able to father children and female patients of childbearing potential&#xD;
             and at risk for pregnancy must agree to use 2 highly effective methods of&#xD;
             contraception throughout the study and for at least 90 days after the last dose of&#xD;
             crizotinib.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving crizotinib or any investigational products.&#xD;
&#xD;
          -  Prior therapy specifically directed against ROS1 fusion genes including crizotinib.&#xD;
&#xD;
          -  Carcinomatous meningitis or leptomeningeal disease.&#xD;
&#xD;
          -  Spinal cord compression unless treated with the patient attaining good pain control&#xD;
             and stable or recovered neurologic function.&#xD;
&#xD;
          -  Ongoing uncontrolled congestive heart failure (CHF) and any of the following within&#xD;
             the 3 months prior to starting study treatment: myocardial infarction, severe/unstable&#xD;
             angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including&#xD;
             transient ischemic attack.&#xD;
&#xD;
          -  Ongoing cardiac dysrhythmias of CTCAE Grade 2, uncontrolled atrial fibrillation of any&#xD;
             grade, or QTc more than 480 msec.&#xD;
&#xD;
          -  History of extensive disseminated/bilateral or known presence of Grade 3 or 4&#xD;
             interstitial fibrosis or interstitial lung disease, including a history of&#xD;
             pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung&#xD;
             disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior&#xD;
             radiation pneumonitis.&#xD;
&#xD;
          -  Pregnant female patients; breastfeeding female patients.&#xD;
&#xD;
          -  Use of drugs or foods including known potent CYP3A4 inhibitors, known potent CYP3A4&#xD;
             inducers and CYP3A4 substrates with narrow therapeutic indices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi cancer center central hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Koto-ku, Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8081064&amp;StudyName=Crizotinib+%28xalkori+%28registered%29%29+Expanded+Access+Protocol+For+The+Treatment+Of+Japanese+Patients+With+Advanced+Non-small+Cell+Lung+Cancer+%28nsclc%29+Harboring+A+Translocation+Or+Inversion+Involving+The+Ros1+Oncogene</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access Protocol</keyword>
  <keyword>crizotinib</keyword>
  <keyword>Xalkori</keyword>
  <keyword>ROS1</keyword>
  <keyword>Japanese</keyword>
  <keyword>A8081064</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

